Abatacept
Based on 3 publication(s) in Google Scholar
Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: ≥99.0%
- CAS 番号: 332348-12-6
- 分子量:84.4 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 Abatacept
More
Customer Validation & Images
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
生物活性
製品説明
Species Reactivity
Human
体内実験
Abatacept exhibits linear PK across the studied doses. The NCA clearance (CL) is 20.8 mL/day/kg, volume (Vss) is 146 mL/kg, and bioavailability (F) of the SC dose dosing is 57.7%[2].
Abatacept (oral; 10 mg/kg; every 2 days) reduces the proportion of activated T cells (CD44highCD62L–) and inhibits the up-regulation of ICOS and CD71 in homozygous DO11.10 RAG-2–/– BALB/c (H-2d/d) mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Lewis rats (6-9 weeks old) with weights of 150-175 g[2]
-
Dosage:10 mg/kg (IV), 20 mg/kg (SC single-dose), 20 mg/kg (SC Multiple-dose) on day 21 with 10 mg/kg SC doses on days 23, 25, 27, and 29
-
Administration:IV or SC
-
Result:Reduced paw edema, and the SC Multiple-dose group showed significantly greater (tobs = 2.50) paw edema reduction compared with the IV dose group.
-
Animal Model:Male Lewis rats (6-9 weeks old) with weights of 150-175 g[2]
-
Dosage:10 mg/kg (IV), 20 mg/kg (SC single-dose), 20 mg/kg (SC Multiple-dose) on day 21 with 10 mg/kg SC doses on days 23, 25, 27, and 29 (Pharmacokinetic Study)
-
Administration:IV or SC
-
Result:The NCA clearance (CL) is 20.8 mL/day/kg, volume (Vss) is 146 mL/kg, and bioavailability (F) of the SC dose dosing is 57.7%.
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Target
CD80 & CD86
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
[CTLA4 (cytotoxic T-lymphocyte-associated protein 4, CD152)]2-IGHG1 Fc (Fragment constant)
Verified Bioactivity
化学情報
-
CAS 番号 332348-12-6
-
性状 Liquid
-
分子量 84.4 kDa
-
Color Colorless to light yellow
-
SMILES
[Abatacept]
-
別名
CTLA4lg; BMS-188667
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
-
Cell Rep
2024 Aug 22;43(9):114664. PMID: 39178113
Abatacept purchased from MedChemExpress. Usage Cited in: Cell Rep. 2024 Aug 22;43(9):114664. [Abstract]
CTLA4-Ig (0.25 mg; ip). Kaplan-Meier curve with log-rank test for graft survival.
Abatacept purchased from MedChemExpress. Usage Cited in: Cell Rep. 2024 Aug 22;43(9):114664. [Abstract]
CTLA4-Ig (0.25 mg; ip). Leukocytes infiltrated in native hearts and allografts of CTLA4-Ig plus CD40-TRAF6i-NB-treated mice 100 days post-transplantation.
Abatacept purchased from MedChemExpress. Usage Cited in: Cell Rep. 2024 Aug 22;43(9):114664. [Abstract]
CTLA4-Ig (0.25 mg; ip). Immune cell subsets in allografts of CTLA4-Ig plus CD40-TRAF6i-NB-treated recipient mice 100 days post-transplantation.
-
純度とドキュメンテーション
-
データシート (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[1]. Kiykim A, et al. Abatacept as a Long-Term Targeted Therapy for LRBA Deficiency. J Allergy Clin Immunol Pract. 2019 Jun 22. [Content Brief]
[2]. Lon HK, et al. Modeling pharmacokinetics/pharmacodynamics of abatacept and disease progression in collagen-induced arthritic rats: a population approach. J Pharmacokinet Pharmacodyn. 2013 Dec;40(6):701-12. [Content Brief]
[3]. Patakas A, et al. Abatacept Inhibition of T Cell Priming in Mice by Induction of a Unique Transcriptional Profile That Reduces Their Ability to Activate Antigen-Presenting Cells. Arthritis Rheumatol. 2016 Mar;68(3):627-38. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Abatacept 関連分類
HY-108829 関連分類
Powered by Bioz